In 2011, the Early Breast Cancer Trialists’ Collaborative Group conducted a patient-level meta-analysis aiming to associate the levels of ER expression with the recurrence reduction with the use of 5-year adjuvant tamoxifen [38]. This evidence concerns the gene ESR1 and breast carcinoma.